Ba Dinh

Researchers are investigating a shorter, 6-month treatment regimen using high doses of rifampicin, isoniazid, linezolid, and pyrazinamide compared to the World Health Organization's standard 9-month treatment for tuberculous meningitis (TBM), a serious brain infection with high risk of death and severe neurological problems. This Phase II, randomized, open-label trial aims to evaluate the safety, drug levels, and long-term outcomes of this intensified 6-month therapy versus the standard treatment. Participants include adults and adolescents diagnosed with TBM, with treatment groups balanced by HIV status and disease severity.